Other

The Brigham and Women's Hospital, Inc.

The Beth Israel Hospital Association

Beth Israel Deaconess Medical Center, Inc.

Beth Israel Hospital Assn.

The General Hospital Corporation

Beth Israel Hospital

Scholar Rock, Inc.

Jeffrey S Flier

Bruce M Spiegelman

Terry Barton Strom

R Tyler White

Kimberly Kafadar Long

Alan C Moses

Yung Chyung

Philip W Gold

Christopher Chapron

Linda A Morrow

Martin C Carey

Ma-Li Wong

Maria Koulmanda

Julio Licinio De Castro Paixao

Barry M Rosen

George Nomikos

Micah T Webster

Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an a1 antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of a1-antitrypsin.

Compositions containing &#x3b1;-1-antitrypsin and methods for use

Methods of treating an affective disorder in an individual are disclosed. Affective disorders include major depression, melancholic and atypical subtypes, and dysthymia.

Methods of neuroendocrine regulation of affective disorders

A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.

Method for modifying, diagnosing and screening for IGF-I sensitive cell

Method for modifying, diagnosing, and screening for IGF-I sensitive cell

Method for treating insulin resistance with IGF-I

The invention provides a recombinant purified human protein in substantial quantities which has both adipsin and complement D activity. The invention also provides materials and methods to produce the protein. In addition, antibodies immunoreactive with this protein are useful to diagnose metabolic defects attributable to adipsin deficiency or complement D deficiency. The protein can be used to treat obesity caused by adipsin deficiency or to treat subjects for infection.

DNA encoding human adipsin with complement D activity

Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of the human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.

Drug administration

Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of a human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.

A composition useful for the treatment of an animal suffering from a predetermined medical disorder including, in admixture, a medically effective amount of a drug, other than an antibiotic, effective against the medical disorder, and a biocompatible, water-soluble, amphiphilic steroid, other than a bile salt, which is capable of increasing the permeability to the drug of a surface of the animal across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.

Growing community of inventors

West Newton, MA, United States of America

Jeffrey S Flier